Page 5 - Agonist News Today

The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that genetic engineering of antibodies used to activate and support the immune system against cancer leads to improvements in their reliability and effectiveness.

— Presentation entitled BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility — — First-in-human Phase 1 trial for lead program, BMB-101,... | April 10, 2023

NASH Renaissance 2023 Pemvidutide-Potent GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH and Obesity Evercore ISI Research... | March 30, 2023

Researchers provide evidence that a novel vaccine candidate robustly neutralized SARS-CoV-2 Omicron subvariants BQ.1.1 and XBB.

Patients with 'blinding' headaches known as Idiopathic Intercranial Hypertension could be treated with an injectable peptide used for type 2 diabetes, a new trial has found.

In the continuing effort to improve upon opioid pain relievers, American and Chinese scientists used cryoEM technology to solve the detailed structures of the entire family of opioid receptors bound to their naturally occurring peptides.

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

Researchers developed a one-dose subunit vaccine for the induction of durable, potent, and broad immunity against SARS-CoV-2.

Opioid-related overdose is now a leading cause of accidental death in the United States and Canada. A study published December 1st in the open access journal PLOS Medicine by Mary Clare Kennedy at University of British Columbia, Kelowna, Canada, and colleagues suggests discontinuing prescribed opioids was associated with increased overdose risk.

Researchers at the University of Michigan Rogel Cancer Center have identified a novel treatment approach to an aggressive type of pediatric brain cancer, using therapies already approved to treat cancer.